Gene Kinney has been the CEO of Prothena Corporation plc (NASDAQ:PRTA) since 2016. First, this article will compare...
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today reported financial results for the first quarter of 2020. In addition, the Company provided an update on its R&D programs and 2020 financial guidance. “While the COVID-19 pandemic has brought significant challenges to people around the world and to our industry, Prothena has acted to protect the health of patients and our employees and the continuity of our programs,” said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena.
Shareholders in Prothena Corporation plc (NASDAQ:PRTA) may be thrilled to learn that the analysts have just delivered...
Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.
Q4 2019 Prothena Corporation PLC Earnings Call
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that members of its senior management team will present and participate in the Jefferies Virtual Healthcare Conference on Wednesday June 3 at 3:30 PM ET. A webcast of the company presentation can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its first quarter of 2020 financial results on Wednesday, May 6, 2020, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 6. Prothena Corporation plc is a clinical-stage neuroscience company with expertise in protein misfolding, focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating diseases.
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 12, 2020 after the close of the U.S. financial markets. To access the call via dial-in, please dial (877) 887-5215 (U.S. and Canada toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 1758808. A replay of the call will be available until February 26, 2020 via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 1758808.
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced the appointment of Brandon Smith as Chief Business Officer. Mr. Smith will be responsible for leading Prothena’s business development initiatives, portfolio strategic planning and alliance management activities. “Brandon is a proven leader with a diverse experience across multiple sectors of the biotech industry and we are pleased to welcome him to our executive team,” said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena.
It is a pleasure to report that the Prothena Corporation plc (NASDAQ:PRTA) is up 55% in the last quarter. But only the...
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease will be presented by Roche in an oral presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD Focus Meeting (AAT-AD/PD), to be held virtually on April 2-5, 2020. Prasinezumab, a monoclonal antibody under development for the potential treatment of Parkinson's disease, is the focus of a worldwide collaboration between Prothena and Roche. Baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson's disease, will be presented in the following virtual oral session.
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) delivered earnings and revenue surprises of 1.67% and -37.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) delivered earnings and revenue surprises of 16.92% and 28.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Net cash used in operating and investing activities was $14.6 million in the fourth quarter and $53.5 million for the full year 2019; quarter-end cash and restricted cash.
NEW YORK, NY / ACCESSWIRE / February 12, 2020 / Prothena Corp. Plc (NASDAQ:PRTA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 12, 2020 at ...
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that in connection with hiring an executive on March 30, 2020, the compensation committee of the Company’s board of directors granted the individual hired by Prothena an option to purchase 120,000 shares of the Company’s common stock. The stock option has an exercise price per share equal to $10.99, which was the closing trading price on April 1, 2020, the date of the grant. The stock option was granted pursuant to the Company’s 2020 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
Prothena Corporation plc (PRTA) today announced a change in the location of its annual general meeting of shareholder scheduled to be held on Tuesday, May 19, 2020. The meeting will convene as scheduled at The Merrion Hotel, Upper Merrion Street, Dublin 2, Ireland, at 4:00 p.m. local time, but will then immediately adjourn and reconvene at the offices of the Company’s legal counsel, A&L Goodbody, North Wall Quay, IFSC, Dublin 1, Ireland, at 4:30 p.m. local time. The Company announced this change in venue due to the COVID-19 pandemic and restrictions issued by governmental authorities in Ireland in response to that pandemic, and to protect the health and safety of the Company’s shareholders, directors, employees, service providers and local community.
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced that today Roche provided an update on Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease. As updated by Roche during its 1Q20 earnings announcement, the study did not meet the primary objective, but showed signals of efficacy. Roche has begun further clinical development planning activities and is evaluating the data from Part 1 of the PASADENA study to determine next steps.